Research progress of novel drug therapy for antibody-mediated rejection in kidney transplantation
10.3760/cma.j.cn112330-20221116-00614
- VernacularTitle:肾移植抗体介导排斥反应新型药物治疗的研究进展
- Author:
Yang YANG
1
;
Zhipeng WANG
;
Jian ZHANG
;
Guangpu DING
;
Wen SUN
;
Lei ZHANG
;
Jun LIN
;
Yichen ZHU
;
Ye TIAN
Author Information
1. 首都医科大学附属北京友谊医院泌尿外科，北京 100050
- Keywords:
Kidney transplantation;
Antibody-mediated rejection;
IgG-degrading enzyme of streptococcus pyogenes;
Fc Neonatal Receptor;
Tocilizumab
- From:
Chinese Journal of Urology
2022;43(12):948-952
- CountryChina
- Language:Chinese
-
Abstract:
Antibody-mediated rejection (AMR) is the primary factor affecting the long-term prognosis of kidney transplant recipients and kidney allograft. Currently, there is no universally recognized or approved drug for the treatment of AMR. Therefore, more novel drug studies and clinical trials are urgently needed in order to change the long-term prognosis of kidney transplant recipients. Based on the core principles of prevention and treatment of AMR, this paper discusses the mechanism and efficacy of several new types of drugs of most concern in the treatment of AMR from three aspects: removing donor specific antibody, blocking antibody-mediated and complement-mediated tissue damage, and inhibiting the proliferation and activation of antibody-producing cells. These emerging drugs have shown potential in preventing and treating AMR and improving the prognosis of recipients, which is expected to change the dilemma of AMR treatment in the future and provide more effective treatment options for improving the long-term prognosis of kidney transplant recipients.
